← Pfizer overview

Pfizer vs Euro/US Dollar FX Spot Rate: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Pfizer Inc (PFE)

Q3 2026
▲3▼1

Pfizer gains on pricing deal, raised guidance, pipeline progress

  • Voluntary drug-pricing deal cuts regulatory risk Pfizer struck a voluntary deal on drug pricing, reducing the threat of new regulations. This lowers uncertainty and helps the company plan without fear of sudden price controls.

    It was a major positive event that reduced regulatory overhang and boosted investor confidence.

  • Q2 earnings beat and 2026 guidance raised Pfizer reported better-than-expected second-quarter results and raised its full-year 2026 revenue forecast to $60.5–$62.5 billion. This signals stronger business performance than previously thought.

    Earnings beats and raised guidance are key drivers of stock price and show improving fundamentals.

  • Cost cuts expanded, pipeline reaches 95 programs Pfizer increased its cost-cutting target to $2.5 billion and now has 95 pipeline programs. Label expansions and new bets in obesity, oncology, Lyme, eczema, and vitiligo aim to boost future revenue.

    Cost savings and pipeline growth are positive for future earnings and show management action.

  • Patent expirations, competition, and debt weigh on outlook Upcoming patent expirations for Ibrance and Eliquis, pricing pressure, Moderna’s new approvals, $60.5 billion debt, and a thinly covered dividend pose risks. Growth was only 1% with a net loss.

    These are significant headwinds that could limit upside and pressure the stock.

September 2026
▲2▼2

Pfizer advances pipeline but faces competition, legal, and financial risks

  • Pipeline and new product momentum Pfizer is advancing growth bets in oncology, obesity, and new drugs like eczema treatment tilrekimig and vitiligo therapy LITFULO. Pipeline programs reached 95, and international new-product sales climbed to $4 billion, showing progress in diversifying beyond COVID.

    This highlights the key positive development that could drive future revenue growth.

  • Cost cuts and productivity gains Cost cuts and tripled sales-force productivity help offset shrinking COVID revenue. This efficiency improvement supports profitability despite top-line pressures.

    This shows management's efforts to improve financial health, a positive factor for the stock.

  • Intensifying competition and guidance concerns Moderna's new COVID and mRNA flu approvals intensify competition, while 2026 guidance sits below 2025 amid patent expirations. This creates uncertainty about Pfizer's ability to grow revenue.

    This is a major negative factor weighing on investor sentiment and future earnings.

  • Financial and legal risks The 6.19% dividend is thinly covered by free cash flow alongside $60.5 billion in debt. Overseas revenue-sharing under the most-favored-nation deal caps pricing upside through 2029, and Monsanto's mRNA patent lawsuit survived dismissal, creating legal and financial uncertainty.

    These factors pose significant risks to Pfizer's financial stability and stock performance.

Latest
▲2▼2

Pfizer's pipeline wins offset pricing and patent setbacks

  • Overseas revenue sharing caps pricing upside Pfizer must share part of any extra overseas drug revenue with the U.S. government under its most-favored-nation pricing deal, running through early 2029. This limits how much Pfizer can profit from higher prices abroad, a direct hit to future earnings and a drag on the stock.

    New pricing rule directly reduces Pfizer's overseas profit potential.

  • New products and cost cuts offset COVID decline Pfizer said new and acquired medicines, vaccines and oncology products grew from $500 million in 2023 to $4 billion internationally, with $3.2 billion in Q2 alone. It also cut costs and tripled sales-force productivity, showing the growth story is delivering as COVID revenue shrinks.

    Shows the core strategy replacing lost COVID revenue is working.

  • Pipeline wins in eczema and vitiligo Pfizer's eczema drug tilrekimig met its Phase 2 goal with strong skin clearance, and LITFULO hit Phase 3 targets in vitiligo, with regulatory filings planned. These are new growth candidates beyond COVID, supporting the long-term pipeline story investors are counting on.

    Two positive trial results add fresh pipeline value beyond existing drugs.

  • Monsanto mRNA patent lawsuit moves forward A Delaware judge rejected Pfizer's bid to dismiss Monsanto's mRNA patent infringement lawsuit over its COVID-19 vaccines. The case now proceeds, creating legal uncertainty and potential financial liability that could weigh on the stock until resolved.

    New legal setback adds uncertainty and potential cost for Pfizer.

▲2▼2

Pfizer's growth bets advance as cash and patent worries weigh

  • Moderna's new approvals add COVID and flu competition Moderna won FDA approval for updated COVID shots and the first mRNA flu vaccine for older adults. That means more rivals fighting for the same pharmacy shelf space and patient visits, which can pressure Pfizer's COVID vaccine sales and slow its push into flu.

    New competitive threat directly affecting Pfizer's respiratory vaccine revenue.

  • Oncology sales and pipeline strengthen Pfizer's cancer business grew 3% to $4.17 billion last quarter, led by Padcev, up 23%, after an FDA approval expanded its patient pool. Pfizer is also testing a promising new cancer drug and aims for eight or more blockbuster cancer medicines by 2030, giving investors a concrete growth engine.

    Shows a real, current revenue driver offsetting declines elsewhere.

  • Obesity and oncology pipeline is the growth story Pfizer now has 95 pipeline programs, with the biggest bets in obesity and cancer. Its monthly obesity shot berobenatide could launch around 2028 in a market expected to reach $114 billion. Progress here is what investors are counting on to replace lost COVID and patent revenue.

    Explains the long-term growth thesis that supports the stock.

  • Dividend and 2026 guidance under pressure Pfizer's 6.19% dividend is only thinly covered by free cash flow, with $60.5 billion of debt competing for the same cash. Management also guided 2026 revenue and earnings below 2025 levels as COVID sales collapse and patents expire. That combination limits financial flexibility and keeps a lid on the stock.

    Highlights the main financial risk weighing on Pfizer's valuation.

August 2026
▲3▼1

Pfizer raises guidance, cuts costs, advances pipeline despite patent and pricing risks

  • Guidance raised on non-COVID drugs Pfizer lifted its 2026 revenue outlook by $500 million, driven by strong sales of non-COVID medicines. This signals that the core business is growing faster than expected, giving investors more confidence in future earnings.

    This is a new positive development that directly boosts investor confidence and is a key reason for the stock's movement.

  • Cost cuts expanded to $2.5 billion Pfizer widened its cost-cutting program to save an additional $2.5 billion. Lower expenses can protect profits even if sales slow, and the move shows management is taking action to improve financial health.

    This is a new operational improvement that supports profitability and is likely to be viewed positively by investors.

  • Pipeline advances: Lyme vaccine and obesity drug Pfizer moved forward its Lyme disease vaccine and obesity drug berobenatide, which could reach the market by 2028. These new products offer future revenue streams as older drugs face patent expirations.

    This is a new pipeline update that addresses long-term growth concerns and is a positive catalyst for the stock.

  • Patent lawsuits and pricing pressure persist Arbutus lawsuits over lipid nanoparticle technology add legal costs and uncertainty, while U.S. drug pricing pressure continues. Overall growth was just 1% with a net loss, and major drugs face patent expirations through 2030.

    These are ongoing risks that weigh on the stock and are important for a balanced view, even though some elements were previously known.

▲3▼1

Pfizer's pipeline advances, but pricing and patent worries persist

  • Obesity drug berobenatide targets 2028 approval Pfizer's lead obesity drug berobenatide is advancing in late-stage trials, with a potential 2028 approval. It aims to compete in a market expected to reach $114 billion by 2030. This offers a major new growth path as older drugs lose patent protection, supporting the stock.

    This is a new pipeline update that could drive future revenue growth, directly answering what's moving PFE.

  • Eliquis strength lifts partner Bristol Myers' outlook Bristol Myers raised its 2026 revenue guidance after Eliquis sales grew 19% in the first half. Pfizer co-markets Eliquis, so it shares in these profits. Stronger-than-expected sales mean more cash for Pfizer, helping offset declines elsewhere and supporting the stock.

    This new update shows a key Pfizer product performing well, directly boosting Pfizer's revenue outlook.

  • FDA approves updated COVID vaccine, EMA reviews Lyme shot The FDA approved Pfizer's XFG-adapted COVID vaccine for high-risk groups, allowing immediate U.S. distribution. Separately, the EMA validated Pfizer's Lyme disease vaccine application. These regulatory wins support near-term COVID sales and add a potential new vaccine revenue stream.

    These are new regulatory milestones that directly affect Pfizer's product sales and pipeline prospects.

  • Drug pricing pressure and patent cliff concerns linger The Trump administration is expected to announce a drug pricing agreement with mid-sized biotech firms, and Pfizer was among major companies urged to cut U.S. prices. Meanwhile, Pfizer's total growth was only 1% and it posted a net loss, with major drugs facing patent expirations through 2030.

    This highlights ongoing regulatory and competitive pressures that could weigh on Pfizer's future revenue and stock.

▲3▼1

Pfizer lifts guidance on non-COVID strength, adds cost savings and Lyme vaccine milestone

  • Pfizer raises 2026 revenue guidance on non-COVID drugs Pfizer beat Q2 estimates and raised its 2026 revenue forecast by $500 million to $60.5–$62.5 billion, driven by strong non-COVID products. This shows the core business is growing and helps offset declining COVID sales, supporting the stock.

    This is the main new positive event of the period and directly boosts investor confidence in Pfizer's growth.

  • Pfizer expands cost-cutting, expects $2.5 billion extra savings Pfizer announced an expansion of productivity initiatives expected to yield $2.5 billion in additional savings between 2027 and 2029, raising total net savings to about $9.7 billion. Lower costs improve future profits and cash flow, which supports the stock.

    This is a new financial development that improves Pfizer's profitability outlook and helps fund its dividend.

  • EMA validates Pfizer-Valneva Lyme disease vaccine application The European Medicines Agency validated the marketing application for Pfizer and Valneva's Lyme disease vaccine candidate, based on Phase 3 efficacy above 70%. If approved, it could be the first such vaccine in Europe, adding a new revenue stream and supporting the stock.

    This is a new regulatory milestone that advances a potential new vaccine product for Pfizer.

  • Arbutus patent lawsuits over lipid nanoparticle technology persist Arbutus filed three international patent infringement lawsuits against Pfizer and BioNTech over lipid nanoparticle technology used in COVID vaccines. This adds legal costs and uncertainty, weighing on the stock.

    This is a new legal development that creates ongoing risk and potential financial liability for Pfizer.

July 2026
▲3▼1

Pfizer gains on pricing deal, earnings beat, label wins

  • Voluntary drug-pricing deal cuts regulatory risk Pfizer struck a voluntary drug-pricing agreement with the Trump administration, easing the threat of forced price cuts. For investors, this lowers a major regulatory overhang and makes future revenue more predictable.

    This is a new, company-specific policy development that reduces a key risk for Pfizer.

  • Q2 earnings beat and raised 2026 guidance Pfizer reported second-quarter results above expectations and raised its full-year 2026 revenue outlook to $60.5–$62.5 billion. The beat and guidance hike signal stronger business momentum than previously thought.

    This is a fresh financial update that directly boosts investor confidence in Pfizer's near-term performance.

  • Label expansions and pipeline advances Pfizer won FDA label expansions for Ibrance and Padcev, got priority review for TALZENNA plus XTANDI, and advanced vitiligo and obesity programs. These broaden existing drugs' use and add future revenue sources.

    These are new regulatory and pipeline wins that expand Pfizer's commercial opportunities.

  • Patent lawsuits and patent-cliff worries persist International patent lawsuits over Comirnaty's lipid nanoparticles and upcoming 2027–2028 expirations for Ibrance and Eliquis keep weighing on Pfizer. These legal and patent risks threaten future sales and create uncertainty.

    This is a new legal development and a continuing overhang that pressures the stock.

▲3▼1

Pfizer's non-COVID drugs and pipeline progress offset COVID decline and patent cliff worries

  • Q2 earnings beat and raised revenue guidance Pfizer beat profit estimates and raised the low end of its 2026 revenue forecast to $60.5–$62.5 billion, driven by strong non-COVID drugs like Eliquis, Padcev, and Vyndaqel. This shows the core business is growing and helps offset declining COVID sales, supporting the stock.

    This is the period's biggest positive catalyst, directly boosting investor confidence in Pfizer's financial outlook.

  • Pipeline wins: LITFULO vitiligo and berobenatide obesity data Pfizer reported positive Phase 3 results for LITFULO in vitiligo and Phase 2b data showing its weight-loss drug berobenatide achieved 16% weight loss. These advance Pfizer's pipeline into new markets, offering future growth to replace aging drugs.

    These pipeline successes are new and show Pfizer's ability to develop new revenue sources, which is key to offsetting the patent cliff.

  • FDA priority review for TALZENNA+XTANDI and EU COVID vaccine authorization The FDA granted priority review to Pfizer's TALZENNA+XTANDI for earlier-stage prostate cancer, and the EU authorized Pfizer's updated COVID-19 vaccine. These regulatory milestones expand market opportunities and support sales in the near term.

    Regulatory progress is a new positive development that can lead to additional revenue streams and shows Pfizer's ability to navigate approvals.

  • Dividend strain and patent cliff concerns persist Pfizer's dividend payout exceeded 130% of earnings, raising concerns about financial strain as major drugs like Ibrance and Eliquis face patent expirations in 2027–2028. Management reaffirmed the dividend, but the high yield reflects investor worries about future cash flows.

    This is a key counterweight to the positive news, highlighting the financial challenges that could pressure the stock if not addressed.

▲3▼1

Pfizer's pipeline wins and pricing deals offset COVID decline and patent cliff

  • FDA approvals expand Ibrance and Padcev labels The FDA approved Ibrance for a new breast cancer type and Padcev with Keytruda for bladder cancer. These label expansions grow Pfizer's oncology sales and help replace falling COVID revenue, supporting the stock.

    New regulatory wins directly boost Pfizer's revenue outlook and investor confidence.

  • Competitor's ATTR-CM trial failure lifts Vyndamax AstraZeneca's ATTR-CM drug failed a late-stage trial, removing a potential rival to Pfizer's Vyndamax. This reduces competition for a $5.4 billion franchise, making Pfizer's rare-disease business more durable.

    Less competition protects a key Pfizer product's sales and pricing power.

  • Voluntary drug-pricing deal with Trump administration Pfizer signed a most-favored-nation pricing agreement, offering discounts on 30+ drugs. While it lowers some prices, it avoids harsher mandates and expands direct-to-consumer sales, providing clarity and reducing regulatory risk.

    The deal removes a major overhang and shows Pfizer adapting to new pricing rules.

  • Patent lawsuits over COVID vaccine technology Arbutus and Roivant filed international patent suits against Pfizer over lipid nanoparticles in Comirnaty, seeking injunctions and damages. This adds legal costs and uncertainty, weighing on the stock.

    New litigation creates financial risk and potential disruption to a major product.

Q2 2026
▼3▲1

Pfizer's mixed June: pipeline wins, leadership exit, policy setback

  • Obesity injection enters late-stage testing Pfizer moved its monthly obesity injection berobenatide into Phase 3 trials, aiming for approval in 2028 in a market that could be worth $120 billion. This gives the company a shot at a big new revenue source.

    This is a major pipeline advance that could drive future growth.

  • Lung cancer trial failure hits Seagen pipeline A Phase 3 trial of sigvotatug vedotin in lung cancer failed, raising doubts about the $43 billion Seagen acquisition. Pfizer shares fell 7.3% on the news, reflecting investor concern about the company's cancer drug prospects.

    This was a significant negative event that directly moved the stock price.

  • CFO departure creates uncertainty Pfizer's Chief Financial Officer is leaving in August, leaving a gap in financial leadership. For investors, a change at the top finance job can raise questions about strategy and execution.

    Leadership changes can affect investor confidence and future direction.

  • COVID drug emergency authorizations ended The termination of COVID-19 drug emergency use authorizations, associated with RFK Jr., reduces sales of Pfizer's Paxlovid. This policy shift cuts into a previously reliable revenue stream.

    This regulatory change directly impacts Pfizer's COVID product sales.

June 2026
▼3▲1

Pfizer's mixed June: pipeline wins, leadership exit, policy setback

  • Obesity injection enters late-stage testing Pfizer moved its monthly obesity injection berobenatide into Phase 3 trials, aiming for approval in 2028 in a market that could be worth $120 billion. This gives the company a shot at a big new revenue source.

    This is a major pipeline advance that could drive future growth.

  • Lung cancer trial failure hits Seagen pipeline A Phase 3 trial of sigvotatug vedotin in lung cancer failed, raising doubts about the $43 billion Seagen acquisition. Pfizer shares fell 7.3% on the news, reflecting investor concern about the company's cancer drug prospects.

    This was a significant negative event that directly moved the stock price.

  • CFO departure creates uncertainty Pfizer's Chief Financial Officer is leaving in August, leaving a gap in financial leadership. For investors, a change at the top finance job can raise questions about strategy and execution.

    Leadership changes can affect investor confidence and future direction.

  • COVID drug emergency authorizations ended The termination of COVID-19 drug emergency use authorizations, associated with RFK Jr., reduces sales of Pfizer's Paxlovid. This policy shift cuts into a previously reliable revenue stream.

    This regulatory change directly impacts Pfizer's COVID product sales.

▲3▼1

Pfizer's obesity pipeline and cheap valuation drive the story

  • Pfizer pushes into next-gen obesity drugs with monthly dosing Pfizer aims to lead in next-generation obesity therapies with monthly dosing, advancing 10 phase 3 studies and targeting 2028 approval. This is a huge potential market, and success could add a major new growth engine, pushing the stock up.

    This is a key new positive development that could drive future revenue growth.

  • Pfizer seen as deep value with potential to double in 3-5 years Pfizer is viewed as a deep value opportunity, trading at a low P/E with a 6.5% dividend yield. Bulls point to the Seagen acquisition, GLP-1 pipeline, and over 20 Phase 3 trials as catalysts that could double the stock over three to five years.

    This highlights the investment case and potential upside, attracting value investors.

  • RFK Jr. ends COVID-19 drug EUAs, hitting Paxlovid sales HHS Secretary RFK Jr. terminated Emergency Use Authorizations for COVID-19 drugs, including Pfizer's Paxlovid. This reduces future sales of the treatment, weighing on revenue and the stock price.

    This is a new regulatory setback that directly impacts a Pfizer product.

  • Pfizer's strong balance sheet fuels acquisition hopes CEO Albert Bourla says Pfizer has a very big balance sheet and can pursue transformative acquisitions. The company could deepen its weight loss portfolio by acquiring Kailera Therapeutics, signaling financial strength and deal capacity.

    This shows Pfizer's ability to grow through M&A, which could boost future earnings.

▲2▼2

Pfizer's mixed pipeline news: obesity bet advances, cancer drug fails, CFO exits

  • CFO departure adds uncertainty Pfizer's CFO Dave Denton will leave on August 15, raising questions about financial leadership and the 2026 outlook. Shares fell on the news. A new CFO search adds near-term uncertainty, which can weigh on the stock until a permanent replacement is named.

    This is a new event that directly affects investor confidence in Pfizer's financial strategy.

  • Lung cancer drug fails Phase 3 trial Pfizer's sigvotatug vedotin did not significantly improve overall survival in a Phase 3 lung cancer trial. The drug came from the $43 billion Seagen acquisition. This setback raises doubts about the Seagen pipeline and pushed the stock down 7.3% on June 25.

    This is a major clinical failure that impacts Pfizer's oncology growth story and investor sentiment.

  • Obesity pipeline advances with monthly injection Pfizer is moving berobenatide into Phase 3 trials, aiming for 2028 approval. It's a monthly GLP-1 shot for obesity, a market expected to reach $120 billion by 2035. Positive Phase 2b data and over 20 planned studies give Pfizer a shot at a lucrative new market.

    This is a new pipeline update that could drive future revenue growth and offsets negative news.

  • IBRANCE approved for expanded breast cancer use The FDA approved IBRANCE for a new type of metastatic breast cancer, making it the first CDK4/6 inhibitor for both HR+ and HER2+ patients. This expands the market for an existing drug and helps offset pipeline setbacks.

    This is a new regulatory approval that strengthens Pfizer's oncology franchise and provides a revenue boost.

Euro/US Dollar FX Spot Rate (EURUSD.FOREX)

Latest
▼3▲1

Euro hits 17-month low as French debt fears and Fed rate bets boost dollar

  • French debt crisis and political gridlock sink euro Investors are dumping French bonds and stocks as public debt heads toward 120% of GDP, pushing the French-German bond spread to 141 basis points. This political and fiscal risk makes the euro less attractive, pushing EURUSD down to its lowest since May 2025.

    This is the main new force driving the euro lower this period.

  • US bond yields surge, Fed rate hike bets rise US 10-year Treasury yields jumped above 5.2%, the highest since 2002, as oil prices climbed and Fed officials backed further rate hikes. Higher US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down.

    This is a key new driver of dollar strength this period.

  • Eurozone inflation beats forecasts, keeping ECB hike pressure alive Eurozone September inflation rose to 3.8%, above the 3.6% forecast, with core inflation up to 2.5%. This keeps pressure on the ECB to raise rates further, which supports the euro by attracting global money into euro deposits.

    This is a new counterweight that could support the euro despite the negative drivers.

  • Energy shock and political risk weigh on euro outlook European gas prices above €80/MWh and the war in Iran disrupting LNG shipments are hurting Europe's economy. Meanwhile, far-right gains in Germany and France's political gridlock add uncertainty. These factors make the euro less attractive, pushing EURUSD down.

    This explains the broader negative backdrop for the euro this period.

Q3 2026
▲2▼1

Euro swings from two-month high to 17-month low as Fed hikes and French debt fears dominate

  • Euro hits two-month high on weak US jobs and split Fed The euro climbed to a two-month high near 1.166 as weak US jobs data and a divided Federal Reserve weakened the dollar, while solid eurozone activity and expected ECB rate hikes supported the currency.

    This explains the euro's peak during the period, driven by US dollar weakness and eurozone strength.

  • Euro plunges to 17-month low on Fed hikes and French debt The euro fell to a 17-month low as Federal Reserve rate hikes, 5.2% Treasury yields, French debt concerns, German far-right election gains, and energy shocks weighed heavily on the currency.

    This captures the main downward driver that pushed the euro to its lowest level in 17 months.

  • ECB rate hikes to 2.50% and resilient PMI offer partial support The European Central Bank raised rates to 2.50% and eurozone business activity remained resilient, providing only partial support to the euro amid broader negative forces.

    This shows the counterweight that limited the euro's decline, balancing the negative drivers.

September 2026
▼3▲1

Euro Falls to 17-Month Low as Dollar Strength and Eurozone Risks Dominate

  • Dollar Strength on Fed Hikes and High Yields The Fed raised rates to 3.75–4.00% and US 10-year yields topped 5.2%, pulling global money into dollar assets. This made the dollar more attractive and pushed the euro down.

    This is a key new force that drove EURUSD lower during the period.

  • Eurozone Political and Fiscal Risks Weigh on Euro France's debt neared 120% of GDP with widening bond spreads, and far-right gains in German elections raised concerns. These risks made investors wary of holding euros.

    New political developments added downward pressure on the euro.

  • Energy Shocks Hurt Europe's Growth Outlook Brent crude rose above $100 and natural gas above €80/MWh, raising costs for European businesses and consumers. This weakened the eurozone economy and weighed on the euro.

    Energy price spikes are a new negative factor for the euro.

  • ECB Hikes and Resilient Economy Support Euro Eurozone inflation hit 3.8%, prompting the ECB to raise rates to 2.50% and signal more tightening. The economy held up with PMI at 53.1, attracting some foreign capital.

    This positive force partially offset the euro's decline and is new this period.

▲2▼2

Eurozone data and ECB signals support euro, but US yields and politics weigh

  • Eurozone economy unexpectedly strong, supports euro The eurozone's business activity index jumped to 53.1 in September, the highest in over three years, beating expectations. A stronger economy makes the euro more attractive and supports further ECB rate hikes, pushing EURUSD up.

    This is new data showing eurozone resilience, which strengthens the euro.

  • ECB officials hint at more rate hikes to fight inflation ECB's Nagel said rates may need to become restrictive, and Makhlouf said the ECB would act if energy prices spill over. BofA expects a December hike. Higher expected euro rates attract global money, pushing EURUSD up.

    New hawkish comments from ECB officials and BofA's forecast reinforce expectations of higher euro rates.

  • US bond yields surge and Fed officials back more hikes The 10-year US Treasury yield rose above 5%, the highest in 19 years, after strong US business activity data. Fed's Collins, Musalem, and Barr supported further rate hikes. Higher US rates make the dollar more attractive, pushing EURUSD down.

    New US data and Fed comments drive dollar strength, a key counterweight to the euro.

  • German political risk and ECB's Lane downplays wage pressure Germany's far-right party won a major regional election, weakening the coalition and raising political uncertainty. ECB's Lane said no strong wage pressure, suggesting fewer hikes. These factors weigh on the euro, pushing EURUSD down.

    New political and monetary developments that could undermine euro strength.

▲1▼1

ECB hikes and signals more, but Fed's first hike in three years lifts dollar

  • Markets price more ECB hikes; banks see 2.75% or higher Money markets now price more than four additional ECB hikes, and banks like Barclays, Goldman and Rabobank expect another 25bp move in December to 2.75%. Expectations of higher-for-longer euro rates attract foreign capital into the euro, supporting EURUSD.

    Shows how far investors expect euro rates to rise, a key support for the euro.

  • Fed hikes to 3.75-4.00%, first rise in three years The Fed raised rates on September 16, six days after the ECB, and strong US retail sales and 3.4% inflation backed the move. Higher US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down to about 1.1450.

    The Fed's hike is the main new force pulling EURUSD down this period.

  • Oil and gas above ECB assumptions keep inflation high Brent above $100 and natural gas above €83/MWh exceed the ECB's worst-case assumptions, so inflation may stay high longer. This keeps the ECB tightening, which supports the euro, but high energy also hurts Europe's growth and can push investors to the dollar.

    Energy prices are the underlying force driving both ECB tightening and euro weakness.

▲3▼1

ECB hikes to 2.50% and signals more, lifting euro despite US rate pushback

  • ECB delivers first hike in two meetings, signals more The ECB raised its deposit rate to 2.50% on September 10, its second hike this year, and said inflation will stay above target through 2028. Higher euro interest rates attract global money into the euro, pushing EURUSD up. Markets now expect at least one more hike by year-end.

    The ECB's actual rate hike and further-hike signal is the main new force lifting the euro.

  • Eurozone economy resilient, ECB raises growth forecast ECB President Lagarde said she was surprised by the economy's resilience, with defense, infrastructure and AI investment supporting growth. The ECB raised its 2026 growth forecast to 0.9%. A stronger economy makes the euro more attractive and supports further rate hikes, pushing EURUSD up.

    Economic resilience gives the ECB room to keep rates high, reinforcing euro strength.

  • US rate-hike odds jump on hot PPI, capping euro US producer price inflation rose 5.4% in August, above expectations, and markets now price a 70% chance of a Fed hike on September 16, up from 61%. Higher expected US rates make dollar deposits more attractive, strengthening the dollar and limiting EURUSD's rise.

    This is the main counterweight: US rate expectations are rising too, which caps the euro's gains.

  • Oil above $100 fuels inflation, keeping ECB hawkish Brent crude surged past $105 as Middle East conflict cut energy exports, pushing eurozone inflation to 3.3%. The ECB hiked to prevent energy costs spreading. While high oil can hurt growth, it keeps the ECB tightening, which supports the euro against the dollar.

    Oil-driven inflation is the reason the ECB is hiking, directly linking energy prices to euro strength.

▲2▼1

ECB hike bets build on energy inflation; US intervention and Fed pushback cap euro

  • Eurozone inflation jumps, ECB hike bets build Eurozone inflation rose to 3.3% in August from 2.9%, driven by energy, and producer prices jumped 5.8%. Officials like Holzmann and Nagel pushed for more tightening, and markets now price a September ECB hike with near certainty. Higher expected euro interest rates pull global money into the euro, pushing EURUSD up.

    Rising euro-area inflation and hawkish ECB signals are the main new force lifting the euro.

  • Banks see ECB hiking further, rates staying higher JPMorgan and BNP Paribas now expect an extra ECB hike in December, and DBS sees the deposit rate at 2.50%, citing sticky inflation and resilient growth. Expectations of higher-for-longer euro rates attract foreign capital into the euro, supporting EURUSD.

    New forecasts of further ECB tightening extend the rate advantage that supports the euro.

  • US euro-selling intervention and Fed pushback weigh on euro European central bankers are frustrated that the US sold euros to buy yen without warning, and Bundesbank's Nagel called it a surprise. The extra euro supply weakens the euro. Meanwhile, Fed's Waller backed holding US rates, and strong August US jobs raised hike odds, both supporting the dollar and pushing EURUSD down.

    This is the main counterweight: US policy actions and data that strengthen the dollar against the euro.

  • ECB's blockchain euro plan could support long-term demand ECB's Schnabel pushed for issuing a blockchain-based euro, rejecting stablecoins, with the Pontes project launching next month. If it makes the euro more useful in digital finance, it could gradually raise demand for euros. But the effect is long-term and small for now, so it is a minor support.

    A new structural initiative that could affect future euro demand, though not an immediate price driver.

August 2026
▲2▼2

Euro Hits Two-Month High on Dollar Weakness, but Gains Capped

  • Dollar Weakness Lifts Euro Weak US jobs data and a split Fed cut September rate-hike odds, pushing the euro to a two-month high near 1.166. Treasury buybacks and Middle East de-escalation also weighed on the dollar.

    This is the main new driver of the euro's rise in August 2026.

  • Strong Eurozone Data and Hawkish ECB Support Euro Strong German trade and solid eurozone activity boosted the euro. The ECB stayed hawkish, with a September hike to 2.50% increasingly expected, making the euro more attractive.

    This is a new positive factor for the euro in August 2026.

  • US Intervention and Fed Comments Cap Euro US intervention selling euros to buy yen added euro supply and strained ECB cooperation. Fed Chair Warsh's Jackson Hole remarks and hot US PCE inflation revived US hike bets, strengthening the dollar.

    These new counterweights limited the euro's gains in August 2026.

  • Risks Tilt Against Euro Falling eurozone inflation expectations threatened ECB resolve, while stalled Iran talks and a possible US-Japan currency alliance kept risks tilted against the euro.

    These new risks prevented further euro strength in August 2026.

▼3▲1

ECB September hike bets build, but Fed pushback caps euro

  • ECB September rate hike increasingly expected The ECB is set to raise its policy rate to 2.50% in September to stop war-driven energy inflation spreading, and official Schnabel said more tightening is needed. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

    A near-certain ECB hike is the main force lifting the euro this period.

  • Fed Chair Warsh hints at a US rate hike At Jackson Hole, Fed Chair Warsh said there is 'work to do' on inflation, lifting the chance of a September US hike to about 57.5% from 35%. Higher expected US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down.

    This is the main new counterweight that pulled the euro back from its highs.

  • Hot US inflation surprise supports the dollar A hotter-than-expected US PCE inflation reading on August 27 pushed US rates and the dollar up, sending EURUSD to about 1.1650. Stronger US inflation keeps the Fed from easing, which supports the dollar and weighs on the euro.

    It shows the US side of the rate story that is capping the euro.

  • US-Japan currency alliance keeps selling euros Citi says the US-Japan interventions reflect an informal currency alliance, with Washington selling euros to buy yen and possibly acting again if EUR/JPY nears 185-186. Extra euro supply in the market weakens the euro against the dollar.

    It is a real, ongoing drag on the euro that readers should not overlook.

▲3▼1

Euro hits two-month high as Fed hike bets fade and ECB stays hawkish

  • Fed rate-hike bets collapse, dollar loses its yield appeal US jobs data stayed weak and the Fed kept rates unchanged with a split committee, so traders cut the chance of a September hike to about 35% from 52% a week earlier. Lower expected US interest rates make dollar deposits less attractive, pushing EURUSD up.

    This is the main new force weakening the dollar and lifting the euro this period.

  • US Treasury buybacks and Middle East de-escalation weaken the dollar The US Treasury said it would more than double its bond buybacks to add market liquidity, which pushed the dollar down broadly and the euro up to about 1.166. Progress in Iran talks to reopen the Strait of Hormuz also cut safe-haven demand for the dollar.

    These are new events that directly weakened the dollar and pushed EURUSD to a two-month high.

  • Eurozone economy strengthens, keeping ECB hike on the table Eurozone business activity hit its highest since last November, with new orders growing fastest in 40 months and hiring rising for the first time this year. ECB official Lane said 3% inflation is too high. A stronger economy and likely ECB hike attract money into the euro.

    New eurozone data and ECB comments support the euro side of the pair.

  • Counterweight: consumers see lower inflation, and Middle East risk lingers Eurozone consumers' inflation expectations fell for a third month, which could soften the ECB's willingness to hike and cap the euro. Iran also threatened a fully offensive military posture after talks stalled, which could revive safe-haven dollar demand and push EURUSD down.

    This is the real counterweight that could stop the euro's rise, so readers get a fair picture.

July 2026
▲2▼2

Euro Rises on ECB Hawkishness and Weak US Data, but Gains Capped

  • ECB Hawkishness and Strong Eurozone Data Support Euro The European Central Bank kept a tough stance, with markets expecting more rate hikes as inflation stayed above target. Strong German and eurozone data, including GDP growth of 0.4% and high confidence, also lifted the euro.

    This explains a key force pushing the euro higher during the period.

  • Weak US Economic Data Weigh on Dollar Soft US inflation reports, weak GDP, and a Federal Reserve that held rates steady made the dollar less attractive. This helped push the euro to a six-week high near 1.1485.

    This highlights a major factor that weakened the dollar and supported the euro.

  • Oil Price Surge and Safe-Haven Demand Limit Euro Gains Oil prices above $100 due to Middle East tensions raised eurozone inflation but also hurt growth and increased bets on Fed rate hikes. This boosted dollar safe-haven demand, capping the euro's rise.

    This shows a counterweight that prevented larger euro gains.

  • Trade Tensions and Intervention Cap Euro Trump's tariff threats and a joint US-Japan intervention selling euros for yen added pressure. Eurozone inflation slowing to 2.8% in June also suggested the ECB might pause, limiting further euro strength.

    This points to other factors that restrained the euro's advance.

▲2▼1

ECB hike bets build as US data and yen intervention whipsaw the dollar

  • ECB signals September hike, lifting euro The ECB held its key rate at 2.25% but strongly hinted at a September hike, and markets now price the deposit rate near 2.7% by year-end and 3% by 2027. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

    This is the main new force lifting the euro this period.

  • US-Japan joint intervention sells euros for yen The US and Japan jointly intervened to support the yen, selling euros to buy yen in a roughly $87 billion operation. This directly increased the supply of euros in the market, pushing the euro down against the dollar and adding geopolitical risk.

    This is a new, direct supply shock to the euro that weighs on EURUSD.

  • US data mixed: weak jobs, strong ISM and hawkish Fed Weak US jobs and soft data weakened the dollar, but strong ISM manufacturing and hawkish Fed comments later supported it. The tug-of-war between US rate-hike and rate-cut expectations keeps EURUSD volatile, with no clear direction from US data alone.

    US data is a key counterweight to the euro's rise, and its mixed nature explains the back-and-forth.

  • Eurozone GDP beats, supporting ECB hike case Eurozone second-quarter GDP rose 0.4%, beating forecasts, and business activity was strong. This supports the case for an ECB rate hike in September, making the euro more attractive to global investors and helping push EURUSD higher.

    Strong eurozone growth reinforces the ECB tightening story that lifts the euro.

▲2▼1

US jobs shock and euro-selling intervention drive euro to seven-week high

  • Weak US jobs report kills Fed rate-hike bets, lifting euro US July payrolls unexpectedly fell by 23,000, the first drop in five months, and wage growth slowed. Traders slashed the chance of a September Fed rate hike to about 44% from 58%. Lower expected US interest rates weaken the dollar, pushing EURUSD up to a seven-week high near 1.157.

    This is the main new force this period: a weak US economy makes the dollar less attractive, directly lifting the euro.

  • US sells euros to buy yen, weakening euro The US Treasury intervened to support the yen by selling euros and buying yen, without telling the ECB first. This directly increased the supply of euros in the market, pushing the euro down against the dollar. The ECB called it shocking, raising fears of strained central-bank cooperation.

    This is a new, direct action that weakens the euro and is a real counterweight to the euro's rally.

  • Strong German trade data supports euro German trade data came in better than expected, adding to signs that Europe's largest economy is holding up. A stronger eurozone economy makes the euro more attractive to global investors, helping push EURUSD higher alongside the weak US jobs news.

    It is a new eurozone-specific factor that supports the euro and helps explain the move to a seven-week high.

▲3▼1

Fed holds, US data weak, eurozone inflation up — euro hits six-week high

  • Fed holds rates, dollar falls broadly The Fed kept its key rate at 3.50–3.75% for a fifth straight meeting, with only three members wanting a hike. Because US rates are not rising, the dollar lost its appeal and fell, pushing EURUSD up to about 1.143.

    A steady Fed directly weakens the dollar, the main force lifting EURUSD this period.

  • Weak US GDP and cooling PCE knock dollar to six-week low US second-quarter GDP grew only 1.5%, below the 2.0% forecast, and core PCE inflation eased to 3.3%. Slower US growth and softer inflation mean the Fed is less likely to hike, weakening the dollar and lifting the euro to a six-week high.

    Soft US data reduce expected US rates, a key driver of dollar weakness and euro strength.

  • Eurozone GDP and confidence beat, inflation accelerates to 2.9% Eurozone second-quarter GDP rose 0.4% and economic confidence hit a five-month high, while July inflation accelerated to 2.9% on higher oil. Stronger growth and sticky inflation strengthen the case for ECB rate hikes, supporting the euro.

    Better eurozone data and higher inflation raise ECB hike odds, boosting the euro's rate appeal.

  • Trump tariff threat and oil spike weigh on euro Trump threatened steep tariffs on the EU after Brussels fined Google $1 billion, and Brent crude jumped over 6% on Iran tensions. Tariffs and costlier energy hurt the eurozone economy, a counterweight that could cap the euro's gains.

    This is the main risk pulling EURUSD down, balancing the positive drivers.

▲2▼1

Oil spike revives ECB hike bets, but dollar strength keeps euro pinned near 1.14

  • ECB signals possible September hike as oil-driven inflation risks rise The ECB held its key rate at 2.25% but President Lagarde strongly hinted at a September hike, calling inflation risks tilted to the upside. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

    This is the main new monetary policy event of the period and directly supports the euro.

  • German 10-year bond yield hits 15-year high on ECB hike expectations Germany's 10-year yield surged to 3.21%, the highest since 2011, as markets priced two more ECB hikes by early 2027. Higher euro-area bond yields make euro deposits more attractive, lifting the euro against the dollar.

    Rising euro yields are a key channel through which ECB hike bets strengthen the euro.

  • Oil above $100 and Middle East attacks boost dollar safe-haven demand and Fed hike bets Houthi attacks on Saudi tankers sent Brent above $100, reigniting US inflation fears. Markets now price an 83% chance of a September Fed hike, up from 52% a week ago. Higher US rates and safe-haven flows strengthen the dollar, pushing EURUSD down.

    This is the main new force pulling EURUSD lower and is the counterweight to the ECB story.

  • SocGen warns oil spike may force ECB hikes but also sap eurozone growth Societe Generale says surging oil and gas could push the ECB to hike to 2.50% in September, but the same energy costs hurt eurozone growth. The bank sees a return above 1.1480 as a big ask, so the net effect on EURUSD is unclear.

    It fairly presents the real counterweight: higher energy prices can both help and hurt the euro.

▲2▼1

US inflation cools, Fed hike bets fade; euro rebounds but oil risks cap gains

  • Soft US CPI and PPI crush Fed rate-hike bets, lifting the euro US June consumer and producer inflation came in below forecasts, so traders slashed the chance of a Fed rate hike this month from 42% to 16% and for the year from 89% to 80%. Lower expected US rates weaken the dollar, pushing EURUSD up to a 3.5-week high near 1.1485.

    This is the main new force this period: softer US inflation directly reduces the dollar's rate advantage, a key driver of EURUSD.

  • Oil surge from Iran conflict cuts both ways for euro Renewed US-Iran fighting and sanctions sent oil up 9%, raising inflation fears. This could force the Fed to hike (dollar-positive) but also revives ECB hike bets (euro-positive). ING warns euro gains may stall above 1.1460 if oil keeps rising, as costlier energy hurts the eurozone economy.

    Oil is a major new factor this period, with a two-sided impact on EURUSD that explains why the euro's rally is capped.

  • ECB officials signal readiness to act, supporting euro ECB's Holzmann said no second-round inflation effects yet but the bank stands ready to act; Nagel urged caution but decisiveness if needed; Rabobank and ING note oil revives ECB hike risk. This keeps euro interest-rate appeal alive, underpinning EURUSD.

    ECB policy stance is a core driver of the euro's value versus the dollar, and this period brought fresh signals.

  • Eurozone inflation slows, ECB expected to hold rates Final June eurozone inflation was 2.8%, down from 3.2%, with core at 2.4%. Nordea expects the ECB to hold rates at its July meeting as a pause, not a pivot. Slower inflation reduces pressure to hike, limiting euro upside.

    This is a counterweight to the euro-positive ECB signals, showing why the euro isn't rising more.

▲3

ECB hawkishness and Middle East tensions drive euro higher

  • ECB signals more rate hikes, supporting euro ECB minutes showed inflation will stay above target until 2027, and markets now price nearly three rate hikes. Higher euro interest rates attract global capital, pushing EURUSD up.

    This is a key new driver: ECB's hawkish stance strengthens the euro.

  • Middle East tensions weaken dollar, lift euro US-Iran ceasefire broke down, with US strikes on Iran. The dollar usually weakens on such geopolitical risk as investors avoid US assets, helping EURUSD rise.

    New escalation in Middle East tensions is a fresh factor pushing the dollar down.

  • Strong German data boosts euro German industrial production and exports rose unexpectedly in May, signaling eurozone economic resilience. A stronger economy supports the euro, pushing EURUSD higher.

    New positive economic data from Germany supports the euro.

  • Fed rate hike bets ease, but volatility may rise Weak US jobs data and stable claims reduced Fed hike odds, weakening the dollar. However, rising FX volatility and hedging demand could cause sharp swings in EURUSD.

    This shows a counterweight: while Fed bets ease, volatility risk remains.

Q2 2026
▼3▲1

Euro Falls to One-Year Low as Fed Hawkishness and Oil Slump Weigh

  • Fed Hawkishness Draws Capital to USD Fed Chair Warsh's hawkish stance, with nine of 19 officials eyeing a year-end rate hike, pulled capital into the US dollar, pushing the euro to a one-year low near 1.1350.

    This is the main force driving the euro down against the dollar.

  • ECB Hikes Alone into Weak Growth The ECB raised rates by itself while the Eurozone economy remained weak, and President Lagarde downplayed inflation, widening the interest rate gap with the US and pressuring the euro.

    It explains why the euro struggled despite an ECB rate hike.

  • Oil Slump Cuts ECB Hike Expectations A sharp drop in oil prices from $115 to around $75 per barrel reduced the chances of further ECB rate hikes, adding to the euro's weakness.

    It shows how falling oil prices indirectly hurt the euro by lowering ECB hike odds.

  • US-Iran Peace Deal and Weak US Payrolls Lift Euro The US-Iran peace deal briefly pushed the euro above 1.1500, and later weak US payrolls (57k vs. 113k expected) sent it to a 1.5-week high, though analysts warn the dollar rally may be overdone.

    It highlights the main positive forces that temporarily lifted the euro.

June 2026
▼3▲1

Euro Falls to One-Year Low as Fed Hawkishness and Oil Slump Weigh

  • Fed Hawkishness Draws Capital to USD Fed Chair Warsh's hawkish stance, with nine of 19 officials eyeing a year-end rate hike, pulled capital into the US dollar, pushing the euro to a one-year low near 1.1350.

    This is the main force driving the euro down against the dollar.

  • ECB Hikes Alone into Weak Growth The ECB raised rates by itself while the Eurozone economy remained weak, and President Lagarde downplayed inflation, widening the interest rate gap with the US and pressuring the euro.

    It explains why the euro struggled despite an ECB rate hike.

  • Oil Slump Cuts ECB Hike Expectations A sharp drop in oil prices from $115 to around $75 per barrel reduced the chances of further ECB rate hikes, adding to the euro's weakness.

    It shows how falling oil prices indirectly hurt the euro by lowering ECB hike odds.

  • US-Iran Peace Deal and Weak US Payrolls Lift Euro The US-Iran peace deal briefly pushed the euro above 1.1500, and later weak US payrolls (57k vs. 113k expected) sent it to a 1.5-week high, though analysts warn the dollar rally may be overdone.

    It highlights the main positive forces that temporarily lifted the euro.

▲1▼1

Eurozone inflation cools, ECB hike bets fade; weak US jobs lift euro

  • Eurozone inflation cools, ECB hike bets fade Eurozone inflation slowed to 2.8% in June, below the 3% forecast, and German inflation also cooled. Traders cut bets on another ECB rate hike, reducing the euro's interest-rate appeal and pushing EURUSD down toward 1.1400.

    This is the main new force weakening the euro this period.

  • Weak US jobs data dents Fed hike expectations US June payrolls rose only 57,000, far below the 113,000 expected, and May's figure was revised down. This cooled bets on near-term Fed tightening, weakening the dollar and lifting the euro to a 1.5-week high above 1.1400.

    This is the main new force supporting the euro at the end of the period.

  • ECB still hawkish, but oil slump complicates ECB President Lagarde defended June's rate hike as necessary, and ING expects one more hike, supporting the euro. But lower oil prices reduce inflation pressure, and Commerzbank warns the ECB may not need to tighten much more, creating mixed signals.

    Shows the counterweight: ECB hawkishness supports the euro but may be fading.

▼3▲1

Euro hits one-year low as Fed hike bets and oil slump outweigh ECB

  • Fed rate-hike bets drive dollar to 13-month high, euro below 1.14 The Fed under Kevin Warsh is expected to raise rates as soon as September, pulling global money into the dollar. The euro fell below 1.1400 to a one-year low near 1.1350, as higher US rates make dollar deposits more attractive than euro ones.

    This is the main force pushing EURUSD down this period.

  • Oil price collapse cuts ECB hike odds, weakening euro support Easing US-Iran tensions and restored Hormuz oil flows sent Brent crude from $115 in May to about $75. Lower energy costs reduce inflation pressure, so traders slashed the chance of a second ECB rate hike from 50% to 20%, removing a key euro support.

    This new oil-driven shift in ECB expectations is a fresh negative for the euro.

  • ECB's Lagarde downplays inflation, signaling no aggressive tightening ECB President Lagarde said the inflation shock needs only a measured response and no forceful action, even as Eurozone PMIs stay weak with German services at a 43-month low. This contrast with the hawkish Fed widens the euro-dollar interest rate gap, pushing EURUSD down.

    Lagarde's stance is a new, direct driver of euro weakness this period.

  • Dollar rally may be overdone; lower oil and weak US data spark rebound On Friday the dollar fell for a second day as lower oil and weak US consumer sentiment cooled Fed hike expectations, lifting the euro 0.43% to 1.1418. Analysts warn the dollar-positive loop may burn out, and BofA still sees euro recovery later in 2026 on German fiscal stimulus.

    This is the real counterweight that could stop or reverse the euro's fall.

▼2▲1

Hawkish Fed under Warsh drives dollar to one-year high, euro to three-month low

  • Fed's hawkish turn under Warsh lifts USD, sinks EUR New Fed Chair Kevin Warsh's first meeting delivered a hawkish dot plot: nine of 19 officials now expect at least one rate hike by year-end. Higher US rates attract global capital to the dollar, pushing EURUSD down to a three-month low near 1.1416.

    This is the dominant new force this period, directly driving the euro to multi-month lows.

  • ECB hikes alone as other central banks hold The ECB raised rates and signaled more to come, but the BoE, SNB, Norges Bank and Riksbank stayed on hold. A lone hiker with weaker regional growth undermines the euro, as markets price downside risks for the euro area.

    Explains why ECB hikes are not supporting the euro, a key counterintuitive driver.

  • US-Iran peace deal briefly lifts euro Trump signed a memorandum with Iran to end the war, easing geopolitical tensions and weakening the safe-haven dollar. The euro rebounded above 1.1500, though the gain was short-lived as Fed rate expectations soon reasserted themselves.

    Shows a real counterweight to dollar strength, even if temporary.

  • Analysts warn dollar rally may be overdone ING cautioned the dollar's surge may not last, arguing the US-Iran deal removes a positive argument for the dollar and markets overestimate the chance of a Fed rate hike. This suggests EURUSD could stabilize or rebound if rate-hike bets fade.

    Provides a fair counterpoint that the dominant dollar-strength trend may reverse.

© 2026 MarketIVWhy